Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome

Abstract
• IRAK1 is overexpressed and activated in ∼25% of MDSs • Genetic and pharmacological inhibition of IRAK1 is effective against human MDSs • IRAK1 is necessary for survival, proliferation, and NF-κB activation in MDS clones • Coinhibition of IRAK1 and BCL2 collaboratively and selectively targets MDS clones